Paradigm Biopharmaceuticals Limited (ASX:PAR)

Australia flag Australia · Delayed Price · Currency is AUD
0.2800
+0.0150 (5.66%)
Sep 5, 2025, 4:10 PM AEST
5.66%
Market Cap111.28M
Revenue (ttm)16.70K
Net Income (ttm)-14.56M
Shares Out397.43M
EPS (ttm)-0.05
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume725,716
Average Volume755,109
Open0.2650
Previous Close0.2650
Day's Range0.2600 - 0.2800
52-Week Range0.1650 - 0.6600
Beta0.33
RSI34.14
Earnings DateAug 25, 2025

About ASX:PAR

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol PAR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.